MCID: URN008
MIFTS: 66

Urinary Bladder Cancer malady

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Urinary Bladder Cancer

Aliases & Descriptions for Urinary Bladder Cancer:

Name: Urinary Bladder Cancer 12 25 14
Bladder Cancer 12 50 25 14
Malignant Tumor of Urinary Bladder 25 29
Malignant Neoplasm of Urinary Bladder 69
Urinary Bladder Neoplasms 42
Cancer of the Bladder 25
Tumor of the Bladder 12
Carcinoma of Bladder 69
Bladder Neoplasm 69
Bladder Tumors 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11054
ICD10 33 C67 C67.9
ICD9CM 35 188 188.9
MeSH 42 D001749
NCIt 47 C2901 C9334

Summaries for Urinary Bladder Cancer

NIH Rare Diseases : 50 bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. most cases of bladder cancer occur sporadically in people with no family history of the condition. risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy. last updated: 11/11/2015

MalaCards based summary : Urinary Bladder Cancer, also known as bladder cancer, is related to superficial urinary bladder cancer and bladder cancer, somatic. An important gene associated with Urinary Bladder Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Bladder cancer and ERK Signaling. The drugs Valstar and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and lymph node, and related phenotypes are homeostasis/metabolism and cellular

Disease Ontology : 12 An urinary system cancer that results_in malignant growth located in the urinary bladder.

Related Diseases for Urinary Bladder Cancer

Diseases related to Urinary Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
id Related Disease Score Top Affiliating Genes
1 superficial urinary bladder cancer 12.2
2 bladder cancer, somatic 11.6
3 eosinophilic cystitis 11.0
4 adult central nervous system mature teratoma 10.5 CCND1 ERBB2 TP53
5 skeletal tuberculosis 10.5 CCND1 CDKN2A ERBB2
6 clear cell hidradenoma 10.5 FGFR3 KRT20 TP53
7 spiradenoma 10.5 FGFR3 KRT20 TP53
8 mycobacterium kansasii 10.5 CCND1 GSTM1 NAT2 TP53
9 brain stem medulloblastoma 10.5 CCND1 CDKN2A TP53
10 brachydactyly tibial hypoplasia 10.4 CCND1 CDKN2A TERT
11 episodic ataxia 10.4 CCND1 CDKN2A MDM2
12 paraphimosis 10.4 CDKN2A KRT20 TP53
13 congenital symblepharon 10.4 IGFBP3 KRAS NAT1 TP53
14 postpoliomyelitis syndrome 10.4 CDKN2A KRAS TP53
15 spastic ataxia 5 10.4 CDKN2A KRT20 TP53
16 giant cell tumor 10.4 KRAS KRT20 TP53
17 acquired hemangioma 10.4 CDKN2A ERBB2 TP53
18 house allergic alveolitis 10.4 CDKN2A MDM2 TP53
19 papillary adenofibroma 10.4 KRAS KRT20 TP53
20 striated muscle rhabdoid tumor 10.4 CCND1 CDKN2A KRAS
21 tabes dorsalis 10.4 KRAS KRT20 TP53
22 apocrine sweat gland neoplasm 10.4 CDKN2A MDM2 RB1
23 vulva squamous cell carcinoma 10.4 CDKN2A ERBB2 KRT20
24 myotonia congenita 10.4 CDKN2A ERBB2 KRT20
25 arthus reaction 10.4 ERBB2 KRAS TP53
26 ossifying fibromyxoid tumor 10.4 CDKN2A KRAS TP53
27 acute mountain sickness 10.4 CDKN1A MDM2 TP53
28 aicardi-goutieres syndrome 10.4 CDKN2A KRAS TP53
29 spondylarthropathy 10.4 CDKN2A MKI67 TP53
30 spinal muscular atrophy with progressive myoclonic epilepsy 10.4 CCND1 CDKN2A KRT20 TP53
31 pacinian tumor 10.4 CDKN2A KRT20 TP53
32 scarlet fever 10.4 CDKN1A MDM2 TP53
33 clear cell adenofibroma 10.4 CDKN2A TP53
34 vascular myelopathy 10.4 CDKN2A MDM2 TP53
35 uterine corpus endometrial stromal sarcoma 10.4 KRAS KRT20 TERT TP53
36 vestibular gland benign neoplasm 10.4 CCND1 CDKN2A KRAS TP53
37 neuroretinitis 10.4 CCND1 KRAS KRT20
38 tamoxifen-related endometrial lesion 10.4 CDKN2A ERBB2 KRAS TP53
39 ectodermal dysplasia 10.4 CCND1 CDKN2A MDM2 TP53
40 vulva adenocarcinoma 10.4 ERBB2 KRT20 TP53
41 allergic contact dermatitis 10.4 CDKN2A KRAS KRT20 TP53
42 linitis plastica 10.4 CDH1 TP53
43 adult medulloblastoma 10.4 CCND1 CDH1 IGFBP3 TP53
44 placental site trophoblastic tumor 10.4 CDKN2A KRT20 TP53
45 his bundle tachycardia 10.4 CCND1 ERBB2 MKI67 TP53
46 cryoglobulinemia 10.4 CDKN2A FGFR3 TP53
47 13q12.3 microdeletion syndrome 10.4 CCND1 CDKN1A CDKN2A FGFR3
48 vascular hemostatic disease 10.4 ERBB2 FGFR3 KRAS
49 ampulla of vater neoplasm 10.4 CDKN2A CDKN2B TP53
50 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53

Comorbidity relations with Urinary Bladder Cancer via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Ischemic Heart Disease
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter Cancer Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Urinary Bladder Cancer:



Diseases related to Urinary Bladder Cancer

Symptoms & Phenotypes for Urinary Bladder Cancer

MGI Mouse Phenotypes related to Urinary Bladder Cancer:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 IGFBP3 KRAS MDM2 NAT1 NAT2 RASSF1
2 cellular MP:0005384 10.46 FGFR3 KRAS MDM2 RASSF1 RB1 TERT
3 endocrine/exocrine gland MP:0005379 10.43 MDM2 RASSF1 RB1 TERT TP53 TSC1
4 growth/size/body region MP:0005378 10.39 TERT TP53 TSC1 CCND1 CDH1 CDKN1A
5 digestive/alimentary MP:0005381 10.38 CCND1 CDH1 CDKN1A CDKN2A ERBB2 FGFR3
6 behavior/neurological MP:0005386 10.36 FGFR3 IGFBP3 KRAS MDM2 RB1 TP53
7 cardiovascular system MP:0005385 10.36 CCND1 CDH1 CDKN1A CDKN2A ERBB2 KRAS
8 integument MP:0010771 10.36 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
9 mortality/aging MP:0010768 10.36 CDKN2B ERBB2 FGFR3 KRAS MDM2 RASSF1
10 immune system MP:0005387 10.34 CCND1 CDH1 CDKN1A CDKN2A CDKN2B FGFR3
11 neoplasm MP:0002006 10.32 MDM2 RASSF1 RB1 TERT TP53 TSC1
12 embryo MP:0005380 10.29 CDH1 CDKN1A CDKN2A ERBB2 KRAS MDM2
13 nervous system MP:0003631 10.23 CCND1 CDKN1A CDKN2A ERBB2 FGFR3 KRAS
14 craniofacial MP:0005382 10.21 CCND1 CDKN1A ERBB2 FGFR3 KRAS MDM2
15 liver/biliary system MP:0005370 10.18 CDKN1A CDKN2A IGFBP3 KRAS MDM2 RASSF1
16 normal MP:0002873 10.18 CCND1 CDH1 ERBB2 FGFR3 KRAS MDM2
17 muscle MP:0005369 10.15 CDKN1A CDKN2A ERBB2 IGFBP3 KRAS MDM2
18 reproductive system MP:0005389 10.13 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2
19 no phenotypic analysis MP:0003012 10.09 CDH1 CDKN1A CDKN2A CDKN2B FGFR3 KRAS
20 limbs/digits/tail MP:0005371 10.08 CDKN1A ERBB2 FGFR3 KRAS MDM2 RB1
21 renal/urinary system MP:0005367 9.92 CDKN1A CDKN2B FGFR3 KRAS MDM2 RB1
22 pigmentation MP:0001186 9.85 CDKN2A IGFBP3 KRAS MDM2 RB1 TP53
23 respiratory system MP:0005388 9.85 CCND1 CDKN1A CDKN2A ERBB2 FGFR3 KRAS
24 skeleton MP:0005390 9.7 TSC1 CCND1 CDKN1A CDKN2A ERBB2 FGFR3
25 vision/eye MP:0005391 9.28 CCND1 CDKN1A CDKN2A FGFR3 KRAS NAT1

Drugs & Therapeutics for Urinary Bladder Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Valstar 17 VALRUBICIN Anthra Pharmaceuticals Approved October 1998

Drugs for Urinary Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 566)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
4
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
5
Benzocaine Approved Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
6
Fibrinolysin Approved Phase 4 9004-09-5
7
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
8 Parecoxib Approved Phase 4 198470-84-7
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-02-2 5743
12
Bupivacaine Approved, Investigational Phase 4,Phase 1 2180-92-9, 38396-39-3 2474
13
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
14
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1 137-58-6 3676
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
17
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
18
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Alverine Approved Phase 4 150-59-4 3678
22
Mesna Approved Phase 4,Phase 2 3375-50-6 598
23
Thiotepa Approved Phase 4,Phase 2 52-24-4 5453
24
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2 2068-78-2, 57-22-7 5978
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
27
Lornoxicam Approved Phase 4 70374-39-9 5282204
28
Ofloxacin Approved Phase 4 82419-36-1 4583
29
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
30
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
31
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
32
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
33
Bethanechol Approved Phase 4 674-38-4 2370
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
35 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
37
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
38
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
39 Hemostatics Phase 4,Phase 2,Phase 3
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antioxidants Phase 4,Phase 3,Phase 2
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1169)
id Name Status NCT ID Phase
1 Cost-Effectiveness in Bladder Cancer Unknown status NCT00126958 Phase 4
2 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
3 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
4 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4
5 Parecoxib for Treatment of Catheter Related Bladder Discomfort Completed NCT02729935 Phase 4
6 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4
7 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
8 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Completed NCT01661166 Phase 4
9 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
10 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4
11 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4
12 TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT Completed NCT01398982 Phase 4
13 TOMUS-Trial Of Mid-Urethral Slings Completed NCT00325039 Phase 4
14 Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT) Recruiting NCT02555163 Phase 4
15 Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer Recruiting NCT02214602 Phase 4
16 Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors Recruiting NCT01446822 Phase 4
17 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4
18 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Recruiting NCT02001857 Phase 4
19 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4
20 The Assessment of POCD After TURBT Under Spinal Anesthesia Recruiting NCT03029676 Phase 4
21 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Recruiting NCT03147599 Phase 4
22 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
23 Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? Active, not recruiting NCT03038321 Phase 4
24 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Active, not recruiting NCT03147586 Phase 4
25 Peri-operative Aspirin Continuation Versus Discontinuation Enrolling by invitation NCT02350543 Phase 4
26 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Not yet recruiting NCT03039543 Phase 4
27 Investigation of Sugammadex in Outpatient Urological Procedures Not yet recruiting NCT03138967 Phase 4
28 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4
29 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4
30 VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate Terminated NCT01777217 Phase 4
31 Mixed Incontinence: Medical Or Surgical Approach? Terminated NCT00803270 Phase 4
32 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4
33 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
34 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
35 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
36 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3
37 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3
38 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
39 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3
40 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3
41 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3
42 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3
43 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unknown status NCT01469221 Phase 3
44 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3
45 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3
46 Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging Unknown status NCT01004211 Phase 3
47 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
48 Efficacy of Diclofenac BCG Irrigations Unknown status NCT01542567 Phase 3
49 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3
50 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3

Search NIH Clinical Center for Urinary Bladder Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Urinary Bladder Cancer

Genetic tests related to Urinary Bladder Cancer:

id Genetic test Affiliating Genes
1 Malignant Tumor of Urinary Bladder 29

Anatomical Context for Urinary Bladder Cancer

MalaCards organs/tissues related to Urinary Bladder Cancer:

39
Prostate, Lung, Lymph Node, T Cells, Endothelial, B Cells, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary Bladder Cancer:

18
The Urinary Bladder

Publications for Urinary Bladder Cancer

Articles related to Urinary Bladder Cancer:

(show top 50) (show all 180)
id Title Authors Year
1
Urinary bladder cancer in adults: a histopathological experience from Madinah, Saudi Arabia. ( 28065960 )
2017
2
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention. ( 28058098 )
2016
3
Nonmuscle-invasive and Muscle-invasive Urinary Bladder Cancer: Image Quality and Clinical Value of Reduced Field-of-view Versus Conventional Single-shot Echo-planar Imaging DWI. ( 26962794 )
2016
4
[THE SOMATIC MUTATIONS AND ABERRANT METHYLATION AS POTENTIAL GENETIC MARKERS OF URINARY BLADDER CANCER]. ( 27455559 )
2016
5
Clinical value of digital image analysis in the diagnosis of urinary bladder cancer, particularly in aggressive tumors: a preliminary report. ( 27543866 )
2016
6
A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. ( 27100215 )
2016
7
A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. ( 27512626 )
2016
8
Optical redox ratio and endogenous porphyrins in the detection of urinary bladder cancer: A patient biopsy analysis. ( 27714989 )
2016
9
Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. ( 28025135 )
2016
10
Unexpected Detection of Urinary Bladder Cancer on Dual Phase 18F-NaF PET/CT in a Patient With Back Pain. ( 27607180 )
2016
11
Outcome of urinary bladder cancer after combined therapies. ( 27974922 )
2016
12
Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. ( 27356691 )
2016
13
Outcome of urinary bladder cancer after combined therapies. ( 27453746 )
2016
14
The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. ( 26631646 )
2016
15
Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. ( 26382667 )
2016
16
Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study. ( 26927070 )
2016
17
Non-occupational Exposure to Agricultural Work and Risk of Urinary Bladder Cancer Among Egyptian Women. ( 27028960 )
2016
18
Radiation therapy outcomes in muscle invasive urinary bladder cancer: A single institution experience. ( 27146766 )
2016
19
Controversial roles played by toll like receptor 4 in urinary bladder cancer; A systematic review. ( 27316642 )
2016
20
Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. ( 27002743 )
2016
21
Estrogen metabolites for the diagnosis of schistosomiasis associated urinary bladder cancer. ( 27014746 )
2016
22
Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. ( 27376129 )
2016
23
SiRNA-mediated silencing of Snail-1 induces apoptosis and alters micro RNA expression in human urinary bladder cancer cell line. ( 27322434 )
2016
24
Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study. ( 27797436 )
2016
25
Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. ( 26862849 )
2016
26
A Real-Time Non-invasive Auto-bioluminescent Urinary Bladder Cancer Xenograft Model. ( 27443377 )
2016
27
Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. ( 27246180 )
2016
28
Common Polymorphisms in GSTA1, GSTM1 and GSTT1 Are Associated with Susceptibility to Urinary Bladder Cancer in Individuals from Balkan Endemic Nephropathy Areas of Serbia. ( 27568660 )
2016
29
Functional polymorphisms in the IL6 gene promoter and the risk of urinary bladder cancer in India. ( 26605964 )
2016
30
Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. ( 26733163 )
2016
31
Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery. ( 27077499 )
2016
32
I^III-tubulin overexpression is linked to agressive tumor features and genetic instability in urinary bladder cancer. ( 28025079 )
2016
33
Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. ( 26547385 )
2016
34
CYP1B1 gene polymorphisms correlate with an increased risk of urinary bladder cancer in India. ( 26707614 )
2016
35
Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis. ( 27596295 )
2016
36
mTOR inhibitors in urinary bladder cancer. ( 27235118 )
2016
37
Silencing expression of the NANOG gene and changes in migration and metastasis of urinary bladder cancer cells. ( 27478472 )
2016
38
Clinical Experiences of Korean Medicine Treatment against Urinary Bladder Cancer in General Practice. ( 27190532 )
2016
39
Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer. ( 27446646 )
2016
40
c.29C>T polymorphism in the transforming growth factor-I^1 (TGFB1) gene correlates with increased risk of urinary bladder cancer. ( 26048435 )
2015
41
Correction: Distinct SNP Combinations Confer Susceptibility to Urinary Bladder Cancer in Smokers and Non-Smokers. ( 26335700 )
2015
42
Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes. ( 26298202 )
2015
43
Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. ( 26313410 )
2015
44
Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients. ( 25647262 )
2015
45
G-protein-coupled receptor 137 accelerates proliferation of urinary bladder cancer cells in vitro. ( 25496438 )
2015
46
Alterations of microsatellite loci GSN and D18S51 in urinary bladder cancer. ( 27418776 )
2015
47
Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. ( 26530373 )
2015
48
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. ( 25070653 )
2014
49
Incidental detection of increased (18)F-FDG uptake and its follow-up in patients with granulomatous prostatitis after BCG treatment for urinary bladder cancer. ( 25397626 )
2014
50
Expression of cytokeratin 7, 20, 14 in urothelial carcinoma and squamous cell carcinoma of the Egyprian urinary bladder cancer. ( 25643514 )
2014

Variations for Urinary Bladder Cancer

ClinVar genetic disease variations for Urinary Bladder Cancer:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
3 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
5 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
6 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
7 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
8 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic/Likely pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
9 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
10 TSC1 NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter) single nucleotide variant Pathogenic rs118203542 GRCh37 Chromosome 9, 135781440: 135781440
11 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 GRCh37 Chromosome 9, 135779172: 135779172
12 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic rs118203419 GRCh37 Chromosome 9, 135797205: 135797205
13 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic rs118203423 GRCh37 Chromosome 9, 135796824: 135796824

Expression for Urinary Bladder Cancer

Search GEO for disease gene expression data for Urinary Bladder Cancer.

Pathways for Urinary Bladder Cancer

Pathways related to Urinary Bladder Cancer according to KEGG:

37
id Name Kegg Source Accession
1 Bladder cancer hsa05219

Pathways related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2
2
Show member pathways
13.79 CCND1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
3
Show member pathways
13.5 CCND1 CDKN1A CDKN2A CDKN2B MDM2 RB1
4
Show member pathways
13.48 CCND1 CDKN1A ERBB2 FGFR3 KRAS MDM2
5
Show member pathways
13.21 CDKN1A CDKN2A CDKN2B MDM2 RB1 TP53
6
Show member pathways
13.03 CDKN1A CDKN2A IGFBP3 MDM2 TP53 TSC1
7
Show member pathways
12.86 CDKN1A CDKN2A KRAS MDM2 TP53
8
Show member pathways
12.83 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2
9
Show member pathways
12.82 CDKN1A ERBB2 FGFR3 KRAS MDM2 TP53
10
Show member pathways
12.73 CCND1 CDKN1A MDM2 RB1 TP53
11 12.7 CCND1 CDKN1A FGFR3 KRAS MDM2 TP53
12
Show member pathways
12.67 CCND1 CDKN1A CDKN2A CDKN2B MDM2 RB1
13
Show member pathways
12.66 CCND1 CDH1 ERBB2 KRAS MDM2 RB1
14 12.6 CCND1 CDKN1A CDKN2A MDM2 MKI67 RB1
15
Show member pathways
12.58 ERBB2 FGFR3 KRAS TP53 TSC1
16 12.53 CCND1 CDKN1A CDKN2A ERBB2 FGFR3 KRAS
17
Show member pathways
12.52 ERBB2 FGFR3 KRAS MDM2 TP53
18
Show member pathways
12.52 CCND1 CDKN1A IGFBP3 MDM2 TP53 TSC1
19 12.52 CCND1 CDKN1A CDKN2A CDKN2B KRAS RB1
20
Show member pathways
12.48 CCND1 CDKN1A CDKN2A CDKN2B RB1 TP53
21
Show member pathways
12.48 CCND1 CDKN1A CDKN2A IGFBP3 MDM2 RB1
22
Show member pathways
12.47 CCND1 CDH1 CDKN1A ERBB2 KRAS MDM2
23
Show member pathways
12.44 CCND1 CDKN1A ERBB2 KRAS MDM2 TP53
24 12.44 CCND1 CDH1 CDKN1A CDKN2A CDKN2B MDM2
25 12.42 CCND1 CDKN1A ERBB2 KRAS MDM2 TP53
26
Show member pathways
12.36 CCND1 CDKN1A MDM2 RB1 TP53
27 12.35 CDKN1A MDM2 RB1 TP53
28 12.34 CCND1 CDKN1A CDKN2A CDKN2B KRAS MDM2
29
Show member pathways
12.33 CCND1 CDKN1A CDKN2A CDKN2B RB1
30 12.33 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2
31 12.29 CDKN1A IGFBP3 MDM2 TP53
32 12.29 CCND1 CDH1 CDKN1A KRAS TP53
33 12.27 CCND1 CDH1 KRAS MDM2 RB1 TP53
34 12.23 CCND1 CDKN1A KRAS MDM2 TP53
35
Show member pathways
12.21 CCND1 CDKN1A CDKN2B KRAS MDM2
36 12.19 CCND1 CDKN1A CDKN2B TERT TP53
37
Show member pathways
12.18 CCND1 CDKN1A ERBB2 MDM2
38 12.18 CDKN1A IGFBP3 MDM2 RB1 TP53
39 12.17 CCND1 CDKN1A CDKN2A KRAS MDM2 TP53
40
Show member pathways
12.12 CCND1 CDKN1A CDKN2A ERBB2 KRAS MDM2
41
Show member pathways
12.12 CCND1 CDKN1A ERBB2 FGFR3 KRAS MDM2
42 12.07 CCND1 KRAS MDM2 TP53
43 12.06 CCND1 CDKN1A CDKN2A ERBB2 KRAS MDM2
44 12.05 CDKN1A CDKN2A IGFBP3 MDM2 RB1 TP53
45 11.97 CCND1 CDKN1A MDM2 RB1 TP53
46 11.97 CCND1 CDKN1A CDKN2A KRAS MDM2 RB1
47 11.96 CCND1 CDKN1A MDM2 RB1
48 11.92 CCND1 CDKN2B RB1 TP53
49
Show member pathways
11.87 CDKN1A MDM2 TP53
50 11.86 CDKN1A CDKN2A ERBB2 GSTM1 MDM2 TP53

GO Terms for Urinary Bladder Cancer

Cellular components related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 CCND1 CDKN1A CDKN2A CDKN2B ERBB2 GSTM1
2 nucleolus GO:0005730 9.63 CDKN1A CDKN2A MDM2 MKI67 TERT TP53
3 cytoplasm GO:0005737 9.58 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2

Biological processes related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.87 CDKN1A CDKN2A CDKN2B IGFBP3 RB1 TP53
2 negative regulation of gene expression GO:0010629 9.86 CDKN1A MDM2 RB1 TERT
3 cell cycle GO:0007049 9.86 CCND1 CDKN1A CDKN2A CDKN2B MKI67 RASSF1
4 regulation of cell cycle GO:0051726 9.81 CCND1 CDKN1A RB1 TSC1
5 G1/S transition of mitotic cell cycle GO:0000082 9.78 CCND1 CDKN1A CDKN2A RB1
6 response to glucocorticoid GO:0051384 9.77 CCND1 CDKN1A KRAS
7 regulation of protein stability GO:0031647 9.77 CDKN2A KRAS TERT
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.75 CDKN1A MDM2 TP53
9 animal organ regeneration GO:0031100 9.72 CCND1 CDKN1A MKI67
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.63 CDKN1A CDKN2B RB1
11 response to magnesium ion GO:0032026 9.62 CCND1 MDM2
12 striated muscle cell differentiation GO:0051146 9.62 KRAS RB1
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MDM2 TERT
14 mitotic G1 DNA damage checkpoint GO:0031571 9.61 CCND1 TP53
15 cellular response to gamma radiation GO:0071480 9.61 CDKN1A MDM2 TP53
16 positive regulation of cellular senescence GO:2000774 9.58 CDKN2A KRAS
17 response to X-ray GO:0010165 9.58 CCND1 CDKN1A TP53
18 negative regulation of immature T cell proliferation in thymus GO:0033088 9.54 CDKN2A ERBB2
19 negative regulation of phosphorylation GO:0042326 9.54 CDKN1A CDKN2A CDKN2B
20 signal transduction by p53 class mediator GO:0072331 9.52 CDKN1A TP53
21 cellular response to actinomycin D GO:0072717 9.49 MDM2 TP53
22 replicative senescence GO:0090399 9.46 CDKN1A CDKN2A TERT TP53
23 Ras protein signal transduction GO:0007265 9.43 CDKN1A CDKN2A KRAS RASSF1 RB1 TP53
24 cell cycle arrest GO:0007050 9.17 CDKN1A CDKN2A CDKN2B RASSF1 RB1 TP53
25 apoptotic process GO:0006915 10.04 CDKN2A FGFR3 IGFBP3 KRT20 RB1 TP53

Molecular functions related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 CCND1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
2 protein kinase binding GO:0019901 9.77 CCND1 CDKN1A CDKN2A CDKN2B TP53
3 enzyme binding GO:0019899 9.72 CCND1 GSTM1 MDM2 RB1 TP53
4 chaperone binding GO:0051087 9.61 TERT TP53 TSC1
5 arylamine N-acetyltransferase activity GO:0004060 9.26 NAT1 NAT2
6 disordered domain specific binding GO:0097718 9.13 MDM2 RB1 TP53
7 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN1A CDKN2A CDKN2B
8 protein binding GO:0005515 10.11 CCND1 CDH1 CDKN1A CDKN2A CDKN2B ERBB2

Sources for Urinary Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....